ACRO Biomedical Co Azione

ACRO Biomedical Co Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di ACRO Biomedical Co (ACBM) al 11 ago 2026 è 193,97 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 86,76 % — una variazione del 123,57% (superiore).

Conversione FCF

193,97 %

YoY

123,57%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di ACRO Biomedical Co ammonta a 2026 193,97 % . Tasso di Conversione FCF (FCF/EBITDA) di ACRO Biomedical Co ammontava a 2025 86,76 % . Diminuisce del 123,57% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

ACRO Biomedical Co Analisi delle Azioni

Cosa fa ACRO Biomedical Co? ACRO Biomedical Co Ltd is a leading company in biomedical technology based in Taipei, Taiwan. The company was established in 2006 and has since successfully established itself in the global market for biomedical products and technologies. The company's vision is to improve people's lives and promote health worldwide through innovative and high-quality products and solutions. Business model: ACRO Biomedical Co Ltd specializes in the development, manufacturing, and marketing of biomedical products and technologies. The company has three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology. Each division focuses on developing products and solutions tailored to the needs of patients and medical professionals. Regenerative Medicine: ACRO Biomedical Co Ltd is a leading provider of regenerative biomedical products. Under this division, the company develops innovative solutions for tissue regeneration, such as bioimplants made from natural tissues and biomaterials to repair or restore damaged tissue. These products are used for the treatment of injuries, chronic diseases, and degenerative conditions. Additionally, ACRO Biomedical Co Ltd has also developed solutions for cosmetic and aesthetic applications. Wound Care: ACRO Biomedical Co Ltd's wound care division specializes in developing products and solutions that help accelerate wound healing, prevent infections, and reduce the risk of complications. The company offers a wide range of products, including antimicrobial and moist wound dressings, which are used for the treatment of acute and chronic wounds such as burns, abrasions, and diabetic foot ulcers. Surgical Technology: ACRO Biomedical Co Ltd's surgical technology division provides healthcare professionals with a wide range of surgical products for various applications, including neurosurgery, plastic surgery, and general surgery. The innovative products offered by ACRO Biomedical Co Ltd for surgical applications include cutting tools, implants, and instruments for minimally invasive procedures. Products: ACRO Biomedical Co Ltd offers a wide range of products for various applications and medical specialties. Some of the company's key products include: - ACL-Bioimplant: A bioimplant for cruciate ligament repair made from human cartilage and biomaterials. - ACRO-CAF: A bone grafting material for bone transplantation. - ACRO-Mixtop: A wound healing agent for the treatment of burns, abrasions, and chronic wounds. - ACRO-OSTEOT: A surgical bone drill for orthopedics and neurosurgery. - ACRO-BioSIS: A tissue adhesive for surgical applications. Summary: ACRO Biomedical Co Ltd is a leading company in biomedical technology that offers innovative solutions for the preservation and restoration of people's health. With its three main divisions: Regenerative Medicine, Wound Care, and Surgical Technology, the company provides a wide range of products and solutions for medical professionals and patients. The company's products are marketed worldwide and are known for their quality, reliability, and effectiveness. ACRO Biomedical Co è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su ACRO Biomedical Co azioni

Tasso di Conversione FCF (FCF/EBITDA) di ACRO Biomedical Co è 193,97 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di ACRO Biomedical Co è passato da 86,76 % a 193,97 %, con una variazione del 123,57 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del ACRO Biomedical Co di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare ACRO Biomedical Co di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — ACRO Biomedical Co

Tutte le Metriche Finanziarie — ACRO Biomedical Co